20 results on '"Rosenbaum, Hanna"'
Search Results
2. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1
3. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study
4. Novel Management of Immune Thrombocytopenia in Gaucher Disease Patients
5. Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol
6. Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment
7. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767–5773.
8. Contribution of Decreased Migration of Monocytes to Impaired Inflammation in Gaucher Disease
9. Gaucher Disease and Multiple Myeloma: A Diagnostic and Treatment Challenge
10. Increased Incidence of Autoimmune and Lymphoproliferative Disorders in Gaucher Patients Accompanied with Significantly Impaired Dendritic Cell Function,
11. Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,
12. Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years
13. Eliglustat Tartrate, a Novel Investigational Oral Substrate Reduction Therapy for Gaucher Disease Type 1: Updated Phase 2 Results.
14. For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.
15. Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment.
16. Diagnostic and Disease Management Algorithms for Gaucher Disease: A Guide for Haematologists
17. Immune Thrombocytopenia in Type I Gaucher Disease.
18. Type I Gaucher Disease and Parkinsonism: Prevalence of Parkinson Disease among Ashkenazi Family Members Who Are Carriers of Gaucher Disease.
19. Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia
20. Rituximab Retreatment in B-Cell Non-Hodgkins Lymphoma Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.